STOPPING CANCER.

The article discusses the annual meeting of the American Association for Cancer Research that was held in April 2014 and annual meeting of the American Society of Clinical Oncology that was held in May 2014. Topics include palbociclib, developed by New York-based pharmaceutical company Pfizer drug that blocks two proteins called cyclin-dependent kinases, its large potential impact to patients with estrogen-receptor positive breast cancer and biomarkers to guide the use of CDK 4/6 inhibitors.